A Covid-19 vaccine made by the pharmaceutical company Pfizer has passed safety and effectiveness tests in early clinical trials, a study revealed today.

The jab, of which the Government has ordered 30million doses, is now another promising candidate for the vaccine considered so crucial to stopping the virus.

Early human trials of the injection, carried out by New York-based Pfizer and universities and hospitals in the US, have produced promising results.

People who received the vaccine produced immune responses on par with – or better than – those who had actually had coronavirus in the past.

And no dangerous side effects were reported among the 36 adults who received the jab in the tests, who most commonly complained of headache and tiredness.

Pfizer’s attempt to make a vaccine, which it has called BNT162b1, is the latest in a line of hopeful trial results, with Britain’s own vaccines made by Oxford University and Imperial College London also showing early signs of success in human testing.